Your browser is no longer supported. Please, upgrade your browser.
CELG Celgene Corporation daily Stock Chart
Celgene Corporation
IndexS&P 500 P/E24.24 EPS (ttm)4.25 Insider Own0.20% Shs Outstand780.18M Perf Week-2.92%
Market Cap80.29B Forward P/E11.70 EPS next Y8.79 Insider Trans-3.60% Shs Float780.18M Perf Month-3.88%
Income3.45B PEG1.17 EPS next Q1.95 Inst Own82.00% Short Float1.75% Perf Quarter-24.31%
Sales12.50B P/S6.42 EPS this Y28.10% Inst Trans-0.23% Short Ratio1.58 Perf Half Y-25.29%
Book/sh12.56 P/B8.19 EPS next Y19.39% ROA13.30% Target Price124.29 Perf Year-8.65%
Cash/sh15.07 P/C6.83 EPS next 5Y20.74% ROE48.70% 52W Range94.55 - 147.17 Perf YTD-1.39%
Dividend- P/FCF19.24 EPS past 5Y11.80% ROI11.70% 52W High-30.07% Beta1.54
Dividend %- Quick Ratio3.50 Sales past 5Y18.30% Gross Margin96.40% 52W Low8.84% ATR2.45
Employees7132 Current Ratio3.70 Sales Q/Q10.20% Oper. Margin36.50% RSI (14)43.88 Volatility2.23% 2.32%
OptionableYes Debt/Eq0.77 EPS Q/Q466.70% Profit Margin31.70% Rel Volume1.50 Prev Close102.65
ShortableYes LT Debt/Eq0.67 EarningsJan 25 BMO Payout0.00% Avg Volume8.61M Price102.91
Recom2.20 SMA20-2.31% SMA50-1.59% SMA200-16.08% Volume12,923,576 Change0.25%
Jan-05-18Downgrade BofA/Merrill Buy → Neutral
Dec-27-17Downgrade Bernstein Outperform → Mkt Perform
Dec-22-17Reiterated Stifel Buy $149 → $130
Dec-08-17Upgrade Atlantic Equities Neutral → Overweight
Oct-27-17Upgrade Morgan Stanley Underweight → Equal-Weight
Oct-27-17Reiterated SunTrust Buy $156 → $127
Oct-27-17Reiterated Barclays Equal Weight $135 → $105
Oct-27-17Downgrade JMP Securities Mkt Outperform → Mkt Perform
Oct-26-17Downgrade Wells Fargo Outperform → Market Perform
Oct-24-17Initiated Guggenheim Buy $160
Oct-23-17Resumed Piper Jaffray Neutral $133
Oct-20-17Reiterated UBS Buy $153 → $146
Oct-20-17Downgrade Robert W. Baird Outperform → Neutral $162 → $136
Oct-20-17Downgrade Citigroup Buy → Neutral
Oct-17-17Initiated Bernstein Outperform
Oct-05-17Downgrade Morgan Stanley Equal-Weight → Underweight
Sep-15-17Reiterated Mizuho Buy $134 → $158
Sep-15-17Initiated RBC Capital Mkts Top Pick $176
Jul-31-17Upgrade Argus Hold → Buy
Jul-28-17Resumed Stifel Buy $155
Jan-22-18 06:45PM  How Juno's CEO broke the $9 billion takeover news to employees, vendors and founders American City Business Journals
05:22PM  Celgene (CELG) Q4 Preview: Will It Beat on Earnings Again? Zacks
04:38PM  Pharma deals, shutdown pact help stocks set more records Associated Press
04:34PM  Celgene to buy Juno for $9 billion Reuters Videos
04:30PM  Why Wynn Resorts, Juno Therapeutics, and FirstEnergy Jumped Today Motley Fool
04:27PM  Here's Why Editas Medicine Gained as Much as 14.2% Today Motley Fool
04:25PM  Will Biotech's Merger 'Spigot' Turn On After Juno, Bioverativ? Investor's Business Daily
04:23PM  Celgene Buys Juno Therapeutics: A Risky $9B Bet Forbes
04:13PM  US STOCKS-Stocks hit record as U.S. senators reach deal to end shutdown Reuters
04:12PM  Celgene Will Buy Juno Therapeutics For $9 Billion; Sanofi Acquires Bioverativ Investor's Business Daily
04:10PM  Closing Bell: LIVE MARKETS BLOG
03:43PM  Energy and technology companies lead US stocks higher Associated Press
03:35PM  Celgene Acquires Company Investigating Cancer Warfare Drug
03:33PM  Why Biotech's $20B Merger Monday May Not Be a Home Run Bloomberg Video
03:31PM  Celgene's $9 Billion Buyout of Juno: Is It a Good Deal for Investors? Motley Fool
03:04PM  Celgene & Juno: The Latest in a Bumper Crop of Biotech M&A?
03:01PM  Hackers Have Stolen $1.5 Million Per Month from Crypto Funds : LIVE MARKETS BLOG
02:56PM  [$$] Big Drugmakers Pay Big Prices for Promising Biotechs The Wall Street Journal
02:39PM  Rupert Murdoch Takes Shot at Facebook, Google Over Fake News : LIVE MARKETS BLOG
02:32PM  Juno Therapeutics (JUNO) Shares Skyrocket on Celgene Buyout InvestorPlace
02:29PM  US STOCKS-Wall St touches records as Senate deals to end shutdown Reuters
02:25PM  3 Stocks Move in Premarket Trading Monday
02:05PM  Why bluebird bio Is Soaring 11.9% Today Motley Fool
01:50PM  [$$] Celgene to Buy Juno Therapeutics for $9 Billion The Wall Street Journal
01:28PM  Bulls charge into Hanesbrands & this airline. Plus, a tra... CNBC Videos
01:24PM  Bitcoin Tanks as South Korea Details Crypto Tax: LIVE MARKETS BLOG
12:51PM  Maryland Tries to Woo Amazon With $5 Billion Aid Package: LIVE MARKETS BLOG
12:24PM  [$$] High Prices Won't Deter Biotech Deals The Wall Street Journal
12:21PM  Why Sorrento Therapeutics Inc Jumped Higher Today Motley Fool
12:20PM  Will These 4 Large-Cap Drug Stocks Be Big Winners This Earnings Season? InvestorPlace
12:09PM  2018s M&A Frenzy Has Begun: Juno Therapeutics Inc (JUNO), Celgene Corporation (CELG) SmarterAnalyst
12:03PM  Immunotherapy Stocks Power Higher on Celgene-Juno Deal
11:30AM  GE Selloff Continues Following BAC Downgrade: LIVE MARKETS BLOG
11:26AM  Celgene to buy Juno for $9 billion to boost cancer pipeline Reuters
11:23AM  Biotech M&A takes off as Sanofi and Celgene spend $20 billion Reuters
11:18AM  Biotech M&A takes off as Sanofi and Celgene spend $20 billion Reuters
11:16AM  Merger Monday for biotech CNBC Videos
11:15AM  Celgene Corporation -- Moody's affirms Celgene at Baa2; stable outlook Moody's
11:09AM  Biotech M&A takes off as Sanofi and Celgene spend $20 billion Reuters
11:00AM  Apple Gets Second Downgrade in As Many Weeks: LIVE MARKETS BLOG
10:44AM  Health-Care Deals Fire Up With Drug Giants Facing Price Pressure Bloomberg
10:33AM  Juno Therapeutics' Stock Soars on Buyout Confirmation Motley Fool
10:30AM  Celgene diversifies portfolio with purchase of Juno Therapeutics American City Business Journals
10:12AM  US STOCKS-Dow under pressure as industrial stocks weigh Reuters
10:11AM  East Coast's Largest Refinery Files for Bankruptcy Protection: LIVE MARKETS BLOG
09:49AM  IMF Is Bullish on Global Growth Following U.S. Tax Cuts: LIVE MARKETS BLOG
09:40AM  Celgenes $9 Billion Juno Deal Could Be This Years Most Expensive Bloomberg
09:13AM  Morning Movers: Juno Soars on Celgene Takeout; GE Slumps on Merrill Cut
09:08AM  Big pharma on a buying spree as Celgene buys Juno and San... CNBC Videos
09:05AM  US STOCKS-Wall St on track to open lower as U.S. shutdown enters third day Reuters
08:47AM  Will These 4 Large-Cap Drug Stocks Be Big Winners This Earnings Season? Zacks
08:29AM  Celgene Purchases Juno Therapeutics for $9 Billion LIVE MARKETS BLOG
07:59AM  Celgene Makes $9 Billion Cancer Treatment Play for Juno Therapeutics
07:56AM  The Index Charts Turn Parabolic InvestorPlace
07:44AM  Stocks making the biggest moves premarket: JUNO, CELG, AIG, HAL, BIVV, ADM, DNKN & more CNBC
07:00AM  Celgene to acquire Juno Therapeutics for $9 billion, or $87 a share MarketWatch
06:44AM  Celgene to Buy Juno for $9 Billion, Signaling Cancer Aspirations Bloomberg
06:35AM  Shares of biotech Juno, already up 50% on deal hopes, skyrocket on actual Celgene $9 billion offer CNBC
06:31AM  Celgene buying Juno Therapeutics for $9 billion CNBC Videos
06:30AM  Celgene Corporation to Acquire Juno Therapeutics, Inc., Advancing Global Leadership in Cellular Immunotherapy Business Wire
Jan-21-18 08:31AM  My 3 Top Stocks for 2018 Motley Fool
Jan-20-18 10:34AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Jan-19-18 05:30PM  Investigational Data Presented at ASCO GI Evaluate ABRAXANE® Regimen for Patients with Locally Advanced Pancreatic Cancer Business Wire
04:39PM  Which Biotech Stocks Could Surprise To The Upside On Earnings? Investor's Business Daily
04:09PM  Netflix, Intel Kick Off Silicon Valley Earnings: Investing Action Plan Investor's Business Daily
02:32PM  Fledgling Biotech Company's Stock Surges
11:22AM  Celgene Could Be Bulking Up Very Fast
09:41AM  A Survey Of Celgene's M&A Strategy Benzinga
08:31AM  Will This Tiny Biotech Be Celgene's Next Takeover Target? Motley Fool
06:45AM  Celgene Corporation Stock Needs More Than a Juno Acquisition to Thrive InvestorPlace
Jan-18-18 09:31PM  3 Heirloom Stocks to Hold Forever Motley Fool
05:24PM  Healthcare: Is Celgene Going to Buy Juno Therapeutics? Motley Fool
03:58PM  Juno Hits 52-Week High on Celgene's Rumored Buyout Interest Zacks
03:13PM  U.S. Investors Swarm China's Biotech Leader
01:39PM  Why BeiGene Is Soaring 13.8% Today Motley Fool
01:24PM  A major cancer drugmaker may need to buy its way out of a looming disaster CNBC
11:24AM  Merck & Co., Inc. Stock Could Still Soar Another 10% From Here InvestorPlace
10:17AM  Company News For Jan 18, 2018 Zacks
10:15AM  M&A Waves Pushing Biotech ETFs Higher Zacks
07:45AM  No Reason To Rush Into Juno Therapeutics Inc Stock After This Big Pop InvestorPlace
Jan-17-18 10:00PM  What's Juno Therapeutics Worth to Celgene? Motley Fool
08:47PM  Netflix, Inc. (NFLX), General Electric Company (GE): Mott Capital Managements Top Winners and Losers of 2017 Insider Monkey
05:03PM  What Happened in the Stock Market Today Motley Fool
03:39PM  Wall Street Reacts To Celgene's Reported Interest In Juno Benzinga
03:14PM  5 Big Biotech Stocks To Buy In 2018 InvestorPlace
01:00PM  How a Juno Takeover Could Boost Celgene Investopedia
12:53PM  Why Celgene's Rumored Acquisition Of Juno Actually Makes Sense Investor's Business Daily
12:08PM  [$$] Celgene Can't Put Away Its Wallet Yet The Wall Street Journal
11:50AM  A Match Made in Heaven? Why a Celgene-Juno Deal Makes 'Perfect Sense'
11:37AM  Why Juno Therapeutics Stock Is Soaring Today Motley Fool
11:16AM  Juno's Stock High on Possible Acquisition
10:32AM  Kyprolis Could Boost Amgens Revenue Growth in 2018 Market Realist
10:23AM  Why Now Is the Perfect Time to Short Juno Therapeutics Inc Stock InvestorPlace
10:22AM  Celgene's 3 Key Financial Ratios (CELG) Investopedia
09:00AM  Is Celgene (CELG) Looking to Take Over Juno Therapeutics? Zacks
07:34AM  Amgens Xgeva Could Witness Revenue Growth in 2018 Market Realist
07:30AM  Celgene Needs a Boost, But Juno Isn't It Bloomberg
06:58AM  Bank of America, Goldman Sachs, Juno and Ford - 5 Things You Must Know
06:55AM  Biotech Stock Roundup: Juno Surges on Acquisition Rumor, Concert Down on Patent News Zacks
12:26AM  PRESS DIGEST- Wall Street Journal - Jan 17 Reuters
Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, and ankylosing spondylitis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company's products also include VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and acute myeloid leukemia (AML); THALOMID to treat patients with multiple myeloma and erythema nodosum leprosum; and RITALIN and FOCALIN XR products. Its clinical stage products comprise OTEZLA for use in treating various immune-inflammatory diseases; luspatercept for beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; AG-881 for glioma with IDH mutations; LSD1 inhibitor to treat non-hodgkin lymphoma and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; and durvalumab, an anti-PDL-1 antibody, for multiple hematological cancers. The company has a strategic collaboration with BeiGene, Ltd. and Nimbus Therapeutics. It also has collaborative agreements with Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; Nurix Inc.; Jounce Therapeutics, Inc.; and Dragonfly Therapeutics, Inc. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Smith Scott AndrewSee RemarksDec 19Option Exercise0.003,410046,233Dec 20 04:05 PM
KELLOGG PETER NSee RemarksDec 19Option Exercise0.003,410044,145Dec 20 04:04 PM
Curran TerrieSee remarksDec 19Option Exercise0.001,76505,690Dec 20 04:03 PM
Alles Mark JSee RemarksDec 19Option Exercise0.004,5500177,738Dec 20 04:02 PM
KAPLAN GILLADirectorDec 05Option Exercise24.979,250230,92685,551Dec 06 04:45 PM
MARIO ERNESTDirectorOct 30Option Exercise31.8013,600432,41271,024Nov 01 04:11 PM
KELLOGG PETER NSee RemarksOct 27Option Exercise0.002,100041,823Oct 31 04:10 PM
HUGIN ROBERT Jsee remarksOct 26Option Exercise31.8162,0201,972,5501,060,106Oct 26 04:44 PM
Curran TerrieSee remarksSep 25Sale143.891,727248,4983,925Sep 26 04:29 PM
KAPLAN GILLADirectorSep 12Option Exercise33.889,250313,39085,551Sep 14 04:35 PM
KAPLAN GILLADirectorSep 12Sale141.569,2501,309,43076,301Sep 14 04:35 PM
CASEY MICHAEL DDirectorSep 05Sale139.039,2501,286,0280Sep 06 06:53 PM
MARIO ERNESTDirectorAug 10Sale130.5218,5062,415,40369,424Aug 14 04:53 PM
KAPLAN GILLADirectorAug 02Sale134.527,5001,008,90076,301Aug 03 04:45 PM
Curran TerrieSee remarksAug 01Option Exercise0.001,50006,210Aug 02 04:38 PM
KELLOGG PETER NSee RemarksAug 01Option Exercise0.0060,000070,833Aug 02 04:37 PM
Smith Scott AndrewSee RemarksJul 28Option Exercise0.005,000045,415Aug 01 05:34 PM
PEHL MICHAEL F.See remarksJul 28Option Exercise0.002,50003,488Aug 01 04:56 PM
HUGIN ROBERT Jsee remarksJul 28Option Exercise0.0044,50001,021,159Aug 01 04:52 PM
Alles Mark JSee RemarksJul 28Option Exercise0.004,2000175,120Aug 01 04:48 PM
MARIO ERNESTDirectorJul 01Option Exercise0.00734087,930Jul 05 07:33 PM
LOUGHLIN JAMES JDirectorJul 01Option Exercise0.00734024,361Jul 05 07:33 PM
Friedman Michael ADirectorJul 01Option Exercise0.0073400Jul 05 07:31 PM
KAPLAN GILLADirectorJul 01Option Exercise0.00734083,801Jul 05 07:32 PM
CASEY MICHAEL DDirectorJul 01Option Exercise0.0073400Jul 05 07:30 PM
COX CARRIE SMITHDirectorJul 01Option Exercise0.00734023,880Jul 05 07:31 PM
BARKER RICHARD WDirectorJul 01Option Exercise0.00734012,066Jul 05 07:29 PM
LOUGHLIN JAMES JDirectorJun 26Option Exercise29.4318,500544,36332,877Jun 27 04:39 PM
LOUGHLIN JAMES JDirectorJun 26Sale133.5718,5002,471,04523,627Jun 27 04:39 PM
HUGIN ROBERT Jsee remarksJun 22Option Exercise29.49178,7205,271,0061,033,909Jun 23 04:02 PM
Friedman Michael ADirectorJun 22Option Exercise59.065,000295,3005,000Jun 23 04:04 PM
Friedman Michael ADirectorJun 22Sale135.005,000675,0000Jun 23 04:04 PM
HUGIN ROBERT Jsee remarksJun 22Sale134.14175,97023,604,616973,909Jun 23 04:02 PM
CASEY MICHAEL DDirectorJun 21Option Exercise33.889,250313,3909,250Jun 23 04:05 PM
Friedman Michael ADirectorJun 21Option Exercise59.065,000295,3005,000Jun 23 04:04 PM
Friedman Michael ADirectorJun 21Sale130.005,000650,0000Jun 23 04:04 PM
CASEY MICHAEL DDirectorJun 21Sale133.059,2501,230,7130Jun 23 04:05 PM
Friedman Michael ADirectorJun 19Option Exercise59.065,000295,3000Jun 20 04:07 PM
MARIO ERNESTDirectorJun 17Option Exercise0.00333087,196Jun 20 04:09 PM
LOUGHLIN JAMES JDirectorJun 17Option Exercise0.00333023,627Jun 20 04:08 PM
Friedman Michael ADirectorJun 17Option Exercise0.0033300Jun 20 04:07 PM
KAPLAN GILLADirectorJun 17Option Exercise0.00333083,067Jun 20 04:08 PM
CASEY MICHAEL DDirectorJun 17Option Exercise0.0033300Jun 20 04:07 PM
VESSEY RUPERTSee remarksJun 15Option Exercise104.164,007417,3584,785Jun 16 04:11 PM
MARIO ERNESTDirectorJun 15Option Exercise0.00375086,863Jun 16 04:11 PM
KAPLAN GILLADirectorJun 15Option Exercise0.00375082,734Jun 16 04:09 PM
LOUGHLIN JAMES JDirectorJun 15Option Exercise0.00375023,294Jun 16 04:10 PM
Haller Julia ADirectorJun 15Option Exercise0.003750575Jun 16 04:09 PM
Friedman Michael ADirectorJun 15Option Exercise0.0037500Jun 16 04:08 PM
BONNEY MICHAEL WDirectorJun 15Option Exercise0.003750375Jun 16 04:06 PM
CASEY MICHAEL DDirectorJun 15Option Exercise0.0037500Jun 16 04:06 PM
VESSEY RUPERTSee remarksJun 15Sale120.184,785575,0380Jun 16 04:11 PM
KAPLAN GILLADirectorJun 01Option Exercise28.979,250267,92682,359Jun 02 04:11 PM
CASEY MICHAEL DDirectorMay 30Option Exercise28.979,250267,926100,612May 31 04:10 PM
LOUGHLIN JAMES JDirectorMay 01Option Exercise28.969,250267,88032,169May 02 04:20 PM
LOUGHLIN JAMES JDirectorMay 01Sale124.009,2501,147,00022,919May 02 04:20 PM
HUGIN ROBERT Jsee remarksApr 10Option Exercise29.0260,0001,741,200973,909Apr 12 04:24 PM
KAPLAN GILLADirectorMar 30Sale123.8314,0331,737,70673,109Mar 31 05:31 PM
KAPLAN GILLADirectorMar 03Option Exercise25.587,500191,81387,142Mar 07 04:37 PM
VESSEY RUPERTSee remarksMar 01Sale124.424,000497,672778Mar 02 04:04 PM
CASEY MICHAEL DDirectorFeb 27Option Exercise25.587,500191,8507,500Mar 01 04:15 PM
CASEY MICHAEL DDirectorFeb 27Sale121.557,500911,6250Mar 01 04:15 PM
MARIO ERNESTDirectorFeb 27Sale121.2412,0001,454,88057,424Aug 31 04:03 PM
VESSEY RUPERTSee remarksFeb 02Option Exercise0.005,62306,773Feb 06 04:14 PM
Celgene Switzerland LLC10% OwnerFeb 01Buy16.00625,00010,000,0003,456,463Feb 01 04:18 PM